BMJ Open

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

Bernd Schweikert, Chiara Malmberg, Mercedes Nuñez, Tatiana Dilla, Christophe Sapin, Susanne Hartz

Corresponding Author: Dr. Bernd Schweikert

ICON plc, Konrad-Zuse-Platz 11, 81829 Munich, Germany

bernd.schweikert@iconplc.com

Supplementary Table 1. Efficacy input data used in the base-case analysis based on data from a related network meta-analysis. [23, 24]

Treatment	Probability of response for chosen criterion		HAQ reduction		PASI response			PASI reduction	
	PsARC	PsARC and PASI90	Responders	Non-responders	PASI75	PASI90	PASI100	Responders	Non-responders
Ixe 80 mg Q4W	53.0%	34.4%	0.51	0.05	70.9%	52.0%	35.4%	18.36	9.49
Sec 300 mg	54.1%[a]	26.5%[a]	0.56	0.14	56.6%[a]	36.8%[a]	22.4%[a]	18.36	8.13

[a]Data derived from a mixed population of bDMARD-naïve and -experienced patients (due to lack of data reported specifically for bDMARD-naïve patients).
DMARD, biologic disease-modifying anti-rheumatic drug; HAQ, Health Assessment Questionnaire; Ixe, ixekizumab, PASI, Psoriasis Area and Severity Index; PASI75, 90, 100, ≥75%, ≥90% or 100% reduction from baseline PASI; PsARC, Psoriatic Arthritis Response Criteria; Q4W, every 4 weeks; Sec, secukinumab.